<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232022000100003</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2020.11.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy]]></article-title>
<article-title xml:lang="es"><![CDATA[Autoanticuerpos: una manifestación de los eventos adversos inmunológicos de la inmunoterapia en cáncer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urrego-Callejas]]></surname>
<given-names><![CDATA[Tomás]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto-Restrepo]]></surname>
<given-names><![CDATA[Juan Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sandoval-Álvarez]]></surname>
<given-names><![CDATA[Simón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chvatal-Medina]]></surname>
<given-names><![CDATA[Mateo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[Gloria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Cellular Immunology and Immunogenetics Group ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia Systemic Vasculitis Study Group ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia Rheumatology Group ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Clínica Las Américas-AUNA  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de Antioquia Department of Internal Medicine Faculty of Medicine]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>29</volume>
<numero>1</numero>
<fpage>3</fpage>
<lpage>8</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232022000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232022000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232022000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT   Introduction:  Immunotherapy with checkpoint inhibitors has shown to be one of the most effective new strategies to treat some types of cancer. However, stopping the suppression induced by the checkpoints, mainly CTLA-4 and PD-1/PD-L1, makes patients prone to develop different immune reactions that can range from mild organ involvement to life-threatening compromises. This highlights the importance that patients should be carefully evaluated during treatment in order to detect and understand these types of manifestations, and find tools for their management.   Objectives:  To determine the autoantibody profile of patients under treatment with checkpoint inhibitors (ICI), with or without symptoms suggestive of rheumatological disease associated with the therapy. The clinical and demographical characteristics of such patients were also analyzed.   Methods:  Patients diagnosed with cancer and under treatment with ICI were recruited. Sera were evaluated with commercial kits to determine the presence of autoantibodies. The presence of immune-related adverse events (irAEs) was evaluated according to the definitions proposed in the guidelines of the American Society of Clinical Oncology.   Results:  Of the twenty-four patients evaluated, fifteen presented with at least one adverse immunological event, where dermatological and musculoskeletal were the most prevalent. Autoantibodies were obtained from the serum of 22 patients. Nineteen of them had at least one autoantibody, with antinuclear and anti-smooth muscle antibodies being the most prevalent.   Conclusion:  The seroprevalence found in our study suggests that autoantibodies may be part of irAEs in patients treated with ICI. However, more studies are required to define the usefulness of autoantibody detection in these patients in order to predict clinical manifestations.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La inmunoterapia con inhibidores de puntos de control (ICC) ha demostrado ser una de las nuevas estrategias más efectivas para tratar varios tipos de cáncer. Sin embargo, al detener la supresión ejercida por los puntos de chequeo, principalmente CTLA-4 y PD-1/PD-L1, algunos pacientes presentan diferentes reacciones inmunológicas (irAE) que pueden ir desde compromiso orgánico leve hasta grave, con riesgo de muerte. Esto hace impor tante que durante el tratamiento los pacientes sean evaluados cuidadosamente, para lograr detectar y entender este tipo de manifestaciones y encontrar herramientas para su manejo.  Objetivos:  Determinar la presencia de autoanticuerpos en un grupo de pacientes en tratamiento con ICC, con o sin clínica sugestiva de enfermedad reumatológica asociada a la terapia. Además, evaluar las características clínicas y demográficas de dichos pacientes.  Métodos:  En este estudio transversal se reclutaron pacientes diagnosticados con cáncer y bajo tratamiento con ICC. En el suero se determinaron autoanticuerpos mediante kits comerciales. La presencia de irAE fue evaluada de acuerdo con las definiciones propuestas en las guías de la Sociedad Americana de Oncología Clínica.  Resultados:  De los 24 pacientes evaluados, 15 presentaron al menos un evento adverso inmunológico, siendo los dermatológicos y los musculoesqueléticos los más prevalentes. Respecto a la presencia de autoanticuerpos, de los 22 sueros analizados 19 presentaban al menos un autoanticuerpo, siendo los anticuerpos antinucleares y antimúsculo liso los más comunes.  Conclusión:  La seroprevalencia encontrada en nuestros pacientes nos sugiere que los auto-anticuerpos podrían hacer parte de las irAE en pacientes tratados con ICC. Sin embargo, se requieren más estudios para lograr definir la utilidad de la determinación de autoanticuerpos en estos pacientes como predictores de manifestaciones clínicas.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Autoimmunity]]></kwd>
<kwd lng="en"><![CDATA[Autoantibodies]]></kwd>
<kwd lng="en"><![CDATA[Nivolumab]]></kwd>
<kwd lng="en"><![CDATA[Pembrolizumab]]></kwd>
<kwd lng="en"><![CDATA[Immunotherapy]]></kwd>
<kwd lng="es"><![CDATA[Autoinmunidad]]></kwd>
<kwd lng="es"><![CDATA[Autoanticuerpos]]></kwd>
<kwd lng="es"><![CDATA[Nivolumab]]></kwd>
<kwd lng="es"><![CDATA[Pembrolizumab]]></kwd>
<kwd lng="es"><![CDATA[Inmunoterapia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van der Vlist]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuball]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Radstake]]></surname>
<given-names><![CDATA[TRD]]></given-names>
</name>
<name>
<surname><![CDATA[Meyaard]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2016</year>
<numero>12</numero>
<issue>12</issue>
<page-range>593-604</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Proverbs-Singh]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Postow]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of the immune-related adverse effects of immune checkpoint inhibitors.]]></article-title>
<source><![CDATA[JAMA Oncol.]]></source>
<year>2016</year>
<numero>2</numero>
<issue>2</issue>
<page-range>1346-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielen]]></surname>
<given-names><![CDATA[MMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Schaardenburg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reesink]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Van De Stadt]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Der Horst-Bruinsma]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[De Koning]]></surname>
<given-names><![CDATA[MHMT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2004</year>
<numero>50</numero>
<issue>50</issue>
<page-range>380-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blank]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Haanen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[TN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer immunology. The "cancer immunogram" visualizing the state of cancer-immune system interactions may spur personalized therapy]]></article-title>
<source><![CDATA[Science]]></source>
<year>2016</year>
<numero>352</numero>
<issue>352</issue>
<page-range>658-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belkhir]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Burel]]></surname>
<given-names><![CDATA[SLe]]></given-names>
</name>
<name>
<surname><![CDATA[Dunogeant]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marabelle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hollebecque]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Besse]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2017</year>
<numero>76</numero>
<issue>76</issue>
<page-range>1747-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Baer]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Albayda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Manno]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Haque]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<numero>76</numero>
<issue>76</issue>
<page-range>43-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Lacchetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Brassil]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caterino]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>1714-68</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrego-Callejas]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoval-Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Wolff]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutaneous and pulmonary sarcoid-like reaction induced by nivolumab.]]></article-title>
<source><![CDATA[J Clin Rheumatol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fundamental mechanisms of immune checkpoint blockade therapy]]></article-title>
<source><![CDATA[Cancer Discov]]></source>
<year>2018</year>
<numero>8</numero>
<issue>8</issue>
<page-range>1069-86</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kontzias]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Velcheti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[LH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2017</year>
<numero>3:e000412</numero>
<issue>3:e000412</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[XJ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2018</year>
<numero>363</numero>
<issue>363</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Topalian]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Hodi]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Gettinger]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, activity, and immune correlates of anti-PD-1 antibody in cancer]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2012</year>
<numero>366</numero>
<issue>366</issue>
<page-range>2443-54</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Callahan]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Chávez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Keegan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khamashta]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune-related adverse events of checkpoint inhibitors]]></article-title>
<source><![CDATA[Nat Rev Dis Primers.]]></source>
<year>2020</year>
<numero>6</numero>
<issue>6</issue>
<page-range>38</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Makarov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Merghoub]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zaretsky]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Desrichard]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic basis for clinical response to CTLA-4 blockade in melanoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<numero>371</numero>
<issue>371</issue>
<page-range>2189-99</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Boada]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bielsa]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Figueras]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Carcereny]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer.]]></article-title>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2017</year>
<numero>153</numero>
<issue>153</issue>
<page-range>1162-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
